ALTHX Stock Overview
Theranexus société anonyme, a biopharmaceutical company, develops drug candidates for the treatment of central nervous system disorders.
Theranexus Société Anonyme Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||€1.94|
|52 Week High||€13.88|
|52 Week Low||€1.51|
|1 Month Change||-8.71%|
|3 Month Change||-18.14%|
|1 Year Change||-84.30%|
|3 Year Change||-66.44%|
|5 Year Change||n/a|
|Change since IPO||-88.10%|
Recent News & Updates
Is Theranexus Société Anonyme (EPA:ALTHX) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Is Theranexus Société Anonyme (EPA:ALTHX) Weighed On By Its Debt Load?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
|ALTHX||FR Pharmaceuticals||FR Market|
Return vs Industry: ALTHX underperformed the French Pharmaceuticals industry which returned 17.6% over the past year.
Return vs Market: ALTHX underperformed the French Market which returned -6.3% over the past year.
|ALTHX Average Weekly Movement||8.9%|
|Pharmaceuticals Industry Average Movement||5.3%|
|Market Average Movement||6.0%|
|10% most volatile stocks in FR Market||10.1%|
|10% least volatile stocks in FR Market||3.5%|
Stable Share Price: ALTHX is more volatile than 75% of French stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: ALTHX's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
Theranexus société anonyme, a biopharmaceutical company, develops drug candidates for the treatment of central nervous system disorders. The company’s lead drug candidate is THN102, which is in Phase II clinical trial to treat sleep/wake disorders. It also develops THN201 for the treatment of neurocognitive disorders linked to Alzheimer's disease; and THN101 to treat neuropathic pain.
Theranexus Société Anonyme Fundamentals Summary
|ALTHX fundamental statistics|
Is ALTHX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ALTHX income statement (TTM)|
|Cost of Revenue||€5.59m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Sep 27, 2022
|Earnings per share (EPS)||-1.78|
|Net Profit Margin||-32,600.00%|
How did ALTHX perform over the long term?See historical performance and comparison
Is Theranexus Société Anonyme undervalued compared to its fair value and its price relative to the market?
Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ALTHX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ALTHX's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: ALTHX is unprofitable, so we can't compare its Price-To-Earnings Ratio to the French Pharmaceuticals industry average.
PE vs Market: ALTHX is unprofitable, so we can't compare its Price-To-Earnings Ratio to the French market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ALTHX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ALTHX is good value based on its Price-To-Book Ratio (0.8x) compared to the FR Pharmaceuticals industry average (2.4x).
How is Theranexus Société Anonyme forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALTHX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ALTHX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ALTHX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ALTHX's revenue (81.3% per year) is forecast to grow faster than the French market (5.8% per year).
High Growth Revenue: ALTHX's revenue (81.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ALTHX's Return on Equity is forecast to be high in 3 years time
How has Theranexus Société Anonyme performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALTHX is currently unprofitable.
Growing Profit Margin: ALTHX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ALTHX is unprofitable, and losses have increased over the past 5 years at a rate of 24.2% per year.
Accelerating Growth: Unable to compare ALTHX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALTHX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9%).
Return on Equity
High ROE: ALTHX has a negative Return on Equity (-69.03%), as it is currently unprofitable.
How is Theranexus Société Anonyme's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: ALTHX's short term assets (€16.2M) exceed its short term liabilities (€2.8M).
Long Term Liabilities: ALTHX's short term assets (€16.2M) exceed its long term liabilities (€4.6M).
Debt to Equity History and Analysis
Debt Level: ALTHX has more cash than its total debt.
Reducing Debt: ALTHX's debt to equity ratio has reduced from 162.1% to 47.2% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if ALTHX has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ALTHX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Theranexus Société Anonyme current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALTHX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALTHX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALTHX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALTHX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ALTHX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Franck Mouthon serves as the Chairman and Chief Executive Officer of Theranexus société anonyme since September 26, 2017. Mr. Mouthon is also an Administrator of France Biotech. Mr. Mouthon has 15 year...
CEO Compensation Analysis
Compensation vs Market: Franck's total compensation ($USD306.41K) is about average for companies of similar size in the French market ($USD288.98K).
Compensation vs Earnings: Franck's compensation has increased whilst the company is unprofitable.
Experienced Management: ALTHX's management team is considered experienced (4.7 years average tenure).
Experienced Board: ALTHX's board of directors are considered experienced (4.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.8%.
Theranexus Société Anonyme's employee growth, exchange listings and data sources
- Name: Theranexus Société Anonyme
- Ticker: ALTHX
- Exchange: ENXTPA
- Founded: 2013
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: €8.867m
- Shares outstanding: 4.57m
- Website: https://www.theranexus.com
Number of Employees
- Theranexus Société Anonyme
- 60 avenue Rockefeller
- Pépinière Laennec
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/25 00:00|
|End of Day Share Price||2022/05/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.